{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:34:39Z","timestamp":1781231679757,"version":"3.54.1"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013093","name":"Science and Technology Planning Project of Shenzen Municipality","doi-asserted-by":"publisher","award":["JCYJ2021032414261403"],"award-info":[{"award-number":["JCYJ2021032414261403"]}],"id":[{"id":"10.13039\/501100013093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270940"],"award-info":[{"award-number":["82270940"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105205","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:45:13Z","timestamp":1770741913000},"page":"105205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["FGFR-driven lung cancer: Dissecting resistance and exploring therapeutic avenues"],"prefix":"10.1016","volume":"221","author":[{"given":"Pengfei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuxuan","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueru","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changchun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105205_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0327588","article-title":"The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer","volume":"20","author":"Abdollahi","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2026.105205_bib2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/0008-5472.CAN-20-2426","article-title":"Inhibition of FGFR Reactivates IFNgamma signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies","volume":"82","author":"Adachi","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105205_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2022.08.016","article-title":"Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19\/18 phase II study","volume":"172","author":"Addeo","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105205_bib4","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.jtho.2019.05.041","article-title":"SWOG S1400D (NCT02965378), a Phase II study of the fibroblast growth factor receptor inhibitor AZD4547 in previously treated patients with fibroblast growth factor pathway-activated stage IV squamous cell lung cancer (Lung-MAP Substudy","volume":"14","author":"Aggarwal","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.lungcan.2021.09.007","article-title":"Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study)","volume":"161","author":"Auliac","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105205_bib6","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","article-title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors","volume":"31","author":"Bahleda","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib7","doi-asserted-by":"crossref","first-page":"7630","DOI":"10.1158\/0008-5472.CAN-10-1489","article-title":"GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling","volume":"70","author":"Bai","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105205_bib8","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1158\/1078-0432.CCR-23-3588","article-title":"The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations","volume":"30","author":"Balasooriya","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105205_bib9","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1158\/1535-7163.MCT-18-0048","article-title":"Preclinical development of U3-1784, a Novel FGFR4 antibody against cancer, and avoidance of its on-target toxicity","volume":"18","author":"Bartz","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105205_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.4534","article-title":"FIERCE-21: Phase 1b\/2 study of docetaxel+ b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R\/R) metastatic urothelial carcinoma (mUCC)","volume":"36","author":"Bellmunt","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib11","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2012-1716","article-title":"FGFR1 gene amplification predicts the antitumor response of FGFR inhibitor LY2874455 in human lung cancer cells","volume":"72","author":"Bi","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105205_bib12","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/1535-7163.MCT-17-0464","article-title":"RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade","volume":"17","author":"Bockorny","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105205_bib13","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1200\/JCO.19.01834","article-title":"Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and fgfr2b-selected gastroesophageal adenocarcinoma","volume":"38","author":"Catenacci","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13046-022-02383-5","article-title":"A first-in-human phase 1\/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors","volume":"41","author":"Chan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105205_bib15","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1038\/s41591-024-03132-1","article-title":"Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial","volume":"30","author":"Cheng","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105205_bib16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1186\/s12885-022-09949-8","article-title":"A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial","volume":"22","author":"Chiba","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105205_bib17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","article-title":"Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC","volume":"16","author":"Chu","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/cac2.12654","article-title":"Efficacy and safety of first-line sintilimab plus anlotinib versus chemotherapy for metastatic non-small cell lung cancer: a phase II, open-label, randomized controlled trial","volume":"45","author":"Chu","year":"2025","journal-title":"Cancer Commun. (Lond)"},{"key":"10.1016\/j.critrevonc.2026.105205_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.3603","article-title":"Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion","author":"Cleary","year":"2020","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib20","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.21037\/tlcr-20-522","article-title":"Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cells","volume":"9","author":"Clement","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105205_bib21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/1535-7163.MCT-15-1010","article-title":"Akt activation mediates acquired resistance to fibroblast growth factor receptor inhibitor BGJ398","volume":"16","author":"Datta","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105205_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-96159-0","article-title":"Molecular mechanisms of the anti-cancer drug, LY2874455, in overcoming the FGFR4 mutation-based resistance","volume":"11","author":"Dehghanian","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105205_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104243","article-title":"84P Targeting small cell lung cancer neuroendocrine heterogeneity via FGFR inhibition","volume":"10","author":"Desai","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2026.105205_bib24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.20892\/j.issn.2095-3941.2023.0137","article-title":"Current progress in cancer treatment by targeting FGFR signaling","volume":"20","author":"Du","year":"2023","journal-title":"Cancer Biol. Med"},{"key":"10.1016\/j.critrevonc.2026.105205_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41698-022-00296-2","article-title":"Activation of CD44\/PAK1\/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer","volume":"6","author":"Elakad","year":"2022","journal-title":"NPJ Precis Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib26","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1158\/2159-8290.CD-22-1441","article-title":"Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer","volume":"13","author":"Facchinetti","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105205_bib27","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1158\/1078-0432.CCR-24-1834","article-title":"Understanding and overcoming resistance to selective fgfr inhibitors across FGFR2-driven malignancies","volume":"30","author":"Facchinetti","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105205_bib28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41698-023-00462-0","article-title":"FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes","volume":"7","author":"Furugaki","year":"2023","journal-title":"NPJ Precis Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib29","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1158\/2767-9764.CRC-24-0137","article-title":"A Phase I Study of KIN-3248, an irreversible small-molecule pan-FGFR inhibitor, in patients with advanced FGFR2\/3-driven solid tumors","volume":"4","author":"Garmezy","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105205_bib30","article-title":"Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1","volume":"8","author":"Gong","year":"2024","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib31","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1158\/1078-0432.CCR-24-0012","article-title":"Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial","volume":"30","author":"Grivas","year":"2024","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105205_bib32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.clon.2021.12.010","article-title":"Real-world efficacy of nintedanib plus docetaxel after progression on immune checkpoint inhibitors: results from the ongoing, non-interventional VARGADO study","volume":"34","author":"Grohe","year":"2022","journal-title":"Clin. Oncol. (R. Coll. Radio. )"},{"key":"10.1016\/j.critrevonc.2026.105205_bib33","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.21037\/tlcr-21-1018","article-title":"Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO","volume":"11","author":"Grohe","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105205_bib34","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/ijc.32224","article-title":"Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models","volume":"145","author":"Grunewald","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105205_bib35","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41591-023-02385-6","article-title":"Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495\/KeyImPaCT trial interim results","volume":"29","author":"Gutierrez","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105205_bib36","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib37","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/bjc.2017.478","article-title":"Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)","volume":"118","author":"Han","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105205_bib38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41392-024-01957-3","article-title":"Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial","volume":"9","author":"Han","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2026.105205_bib39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lungcan.2016.10.011","article-title":"Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): a randomized, double-blind, phase III trial","volume":"102","author":"Hanna","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105205_bib40","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.annonc.2023.04.193","article-title":"P-137 Phase 1\/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and\/or FGFR3 gene alterations","volume":"34","author":"Harding","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005414","article-title":"Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer","volume":"5","author":"Harding","year":"2013","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.critrevonc.2026.105205_bib42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2018.02.015","article-title":"Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms","volume":"119","author":"Hegab","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105205_bib43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/path.5290","article-title":"Effect of FGF\/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts","volume":"249","author":"Hegab","year":"2019","journal-title":"J. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib44","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtho.2025.05.016","article-title":"Lenvatinib plus pembrolizumab, pemetrexed, and a platinum as first-line therapy for metastatic nonsquamous NSCLC: phase 3 LEAP-006 Study","volume":"20","author":"Herbst","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib45","doi-asserted-by":"crossref","first-page":"236","DOI":"10.21037\/tlcr-23-705","article-title":"High-resolution genomic configuration of FGFR rearrangements dictates the therapeutic vulnerability of squamous cell lung cancers","volume":"13","author":"Hong","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105205_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215867","article-title":"FGFR1\/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression","volume":"547","author":"Hu","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105205_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/1759-7714.70016","article-title":"A comprehensive analysis of FGF\/FGFR signaling alteration in NSCLC: implications in prognosis and microenvironment","volume":"16","author":"Huang","year":"2025","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105205_bib48","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1038\/s41467-020-17914-x","article-title":"FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy","volume":"11","author":"Im","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105205_bib49","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1158\/0008-5472.CAN-20-4048","article-title":"Upregulation of FGF9 in lung adenocarcinoma transdifferentiation to small cell lung cancer","volume":"81","author":"Ishioka","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105205_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.662","article-title":"A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1","volume":"43","author":"Iyer","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2017.17","article-title":"MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells","volume":"6","author":"Jakobsen","year":"2017","journal-title":"Oncogenesis"},{"key":"10.1016\/j.critrevonc.2026.105205_bib52","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e20661","article-title":"Early clinical experience with the pan-FGFR inhibitor rogaratinib in patients with non-small cell lung cancer selected based on FGFR mRNA expression levels","volume":"37","author":"Joerger","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2026.105205_bib54","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib55","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s11523-019-00670-4","article-title":"First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer","volume":"14","author":"Kim","year":"2019","journal-title":"Target Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2016.48","article-title":"Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy","volume":"5","author":"Kim","year":"2016","journal-title":"Oncogenesis"},{"key":"10.1016\/j.critrevonc.2026.105205_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.633410","article-title":"MET-Pyk2 axis mediates acquired resistance to FGFR inhibition in cancer cells","volume":"11","author":"Kitowska","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib58","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/bjc.2017.137","article-title":"Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group","volume":"117","author":"Koinis","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105205_bib59","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s10637-021-01146-x","article-title":"A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer","volume":"39","author":"Kollmannsberger","year":"2021","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.critrevonc.2026.105205_bib60","first-page":"568","article-title":"Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy","volume":"2","author":"Lau","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.critrevonc.2026.105205_bib61","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jtho.2025.05.020","article-title":"LEAP-008: lenvatinib plus pembrolizumab for metastatic NSCLC that has progressed after an anti-programmed cell death protein 1 or anti-programmed cell death ligand 1 plus platinum chemotherapy","volume":"20","author":"Leighl","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib62","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1038\/s41388-020-1227-2","article-title":"Enhanced autocrine FGF19\/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104","volume":"39","author":"Li","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105205_bib63","article-title":"LY2874455 and Abemaciclib Reverse FGF3\/4\/19\/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105205_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117897","article-title":"Current insights and barriers in FGFR-mediated signaling in lung cancer","volume":"296","author":"Liu","year":"2025","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.critrevonc.2026.105205_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2022.104577","article-title":"FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma","volume":"379","author":"Lu","year":"2022","journal-title":"Cell Immunol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102543","article-title":"Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial","volume":"70","author":"Ma","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2026.105205_bib67","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-17-0478","article-title":"Mechanisms of primary drug resistance in FGFR1-amplified lung cancer","volume":"23","author":"Malchers","year":"2017","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105205_bib68","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170217","article-title":"Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer","volume":"133","author":"Malchers","year":"2023","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.critrevonc.2026.105205_bib69","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1200\/JCO.2025.43.16_suppl.3147","article-title":"A phase II basket trial evaluating the efficacy of tasurgratinib (E7090) in patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE study","volume":"43","author":"Matsubara","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib70","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF\/FGFR Aberrations: a Phase I Dose-Expansion Study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105205_bib71","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5114\/aoms.2020.91284","article-title":"The association between fibroblast growth factor receptor 1 gene amplification and lung cancer: a meta-analysis","volume":"16","author":"Miao","year":"2020","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.critrevonc.2026.105205_bib72","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11523-017-0502-9","article-title":"A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer","volume":"12","author":"Michael","year":"2017","journal-title":"Target Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib73","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.lungcan.2019.08.011","article-title":"An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer","volume":"136","author":"Morgensztern","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105205_bib74","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"Nogova","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib75","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ejca.2015.04.026","article-title":"Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: a double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)","volume":"51","author":"O'Brien","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105205_bib76","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1158\/1078-0432.CCR-17-0645","article-title":"A phase Ib open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers","volume":"23","author":"Paik","year":"2017","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105205_bib77","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/2326-6066.CIR-18-0595","article-title":"The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity","volume":"7","author":"Palakurthi","year":"2019","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.critrevonc.2026.105205_bib78","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12943-024-02167-9","article-title":"Clinical advances and challenges in targeting FGF\/FGFR signaling in lung cancer","volume":"23","author":"Peng","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105205_bib79","article-title":"Successful Treatment and Retreatment With Erdafitinib for a Patient With FGFR3-TACC3 Fusion Squamous NSCLC: a case Report","volume":"4","author":"Pham","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.critrevonc.2026.105205_bib80","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.7150\/jca.44476","article-title":"mRNA expression of FGFR1 as potential marker for predicting prognosis of surgical resection of small cell lung cancer may be better than protein expression and gene amplification","volume":"11","author":"Qin","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105205_bib81","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1172\/JCI38017","article-title":"Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice","volume":"119","author":"Qing","year":"2009","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.critrevonc.2026.105205_bib82","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s42004-021-00623-x","article-title":"Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors","volume":"5","author":"Qu","year":"2022","journal-title":"Commun. Chem."},{"key":"10.1016\/j.critrevonc.2026.105205_bib83","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1038\/s41598-018-20570-3","article-title":"The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction","volume":"8","author":"Quintanal-Villalonga","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105205_bib84","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2019.02.007","article-title":"FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective","volume":"131","author":"Quintanal-Villalonga","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105205_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102683","article-title":"FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy","volume":"53","author":"Quintanal-Villalonga","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105205_bib86","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.1038\/s41388-019-0887-2","article-title":"Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer","volume":"38","author":"Raoof","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105205_bib87","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11092475","article-title":"FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)","volume":"11","author":"Raphael","year":"2022","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.critrevonc.2026.105205_bib88","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib89","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.21037\/tlcr-24-326","article-title":"A non-interventional biomarker study in patients with adenocarcinoma of the lung treated with nintedanib plus docetaxel following progression on chemotherapy and\/or immunotherapy: LUME-BioNIS","volume":"13","author":"Reck","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105205_bib90","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","article-title":"Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial","volume":"30","author":"Rodon","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105205_bib91","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-023-01761-7","article-title":"Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF\/FGFR signaling in tumor microenvironment","volume":"22","author":"Ruan","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105205_bib92","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1541-7786.MCR-18-0429","article-title":"The FGFR1 V561M gatekeeper mutation drives AZD4547 resistance through STAT3 activation and EMT","volume":"17","author":"Ryan","year":"2019","journal-title":"Mol. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105205_bib93","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1111\/cas.15529","article-title":"Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer","volume":"113","author":"Sakashita","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2026.105205_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103625","article-title":"Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies","volume":"9","author":"Saleh","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2026.105205_bib95","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/JTO.0000000000000005","article-title":"An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer","volume":"8","author":"Scagliotti","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib96","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2317756121","article-title":"Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2","volume":"121","author":"Schonherr","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105205_bib97","doi-asserted-by":"crossref","first-page":"IA006","DOI":"10.1158\/1535-7163.TARG-23-IA006","article-title":"Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: the ReFocus study","volume":"22","author":"Schram","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105205_bib98","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(19)30412-7","article-title":"Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Schuler","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib99","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.2024.42.16_suppl.8515","article-title":"Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial","volume":"42","author":"Schuler","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib100","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105205_bib101","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1021\/acschembio.5b00014","article-title":"Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy","volume":"10","author":"Sohl","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib102","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s10637-021-01061-1","article-title":"FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment","volume":"39","author":"Song","year":"2021","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.critrevonc.2026.105205_bib103","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105205_bib104","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1002\/cncr.31290","article-title":"Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures","volume":"124","author":"Spigel","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105205_bib105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib106","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","article-title":"FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib107","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105205_bib108","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/bjc.2017.465","article-title":"Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)","volume":"118","author":"Sun","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105205_bib109","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-4835","article-title":"LY3076226, a novel anti-FGFR3 antibody drug conjugate exhibits potent and durable anti-tumor activity in tumor models harboring FGFR3 mutations or fusions","volume":"79","author":"Surguladze","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105205_bib110","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s40265-022-01806-z","article-title":"Futibatinib: First Approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2026.105205_bib111","doi-asserted-by":"crossref","first-page":"E4869","DOI":"10.1073\/pnas.1403438111","article-title":"Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors","volume":"111","author":"Tan","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105205_bib112","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41698-021-00208-w","article-title":"Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells","volume":"5","author":"Terp","year":"2021","journal-title":"NPJ Precis Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib113","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/annonc\/mdv591","article-title":"A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors","volume":"27","author":"Tolcher","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib114","article-title":"A novel anti-FGFR1 monoclonal antibody OM-RCA-01 exhibits potent antitumor activity and enhances the efficacy of immune checkpoint inhibitors in lung cancer models","volume":"23","author":"Tsimafeyeu","year":"2024","journal-title":"Immunooncol Technol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib115","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1021\/acs.jmedchem.3c01819","article-title":"Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and\/or FGFR3 Gene Alterations","volume":"67","author":"Tyhonas","year":"2024","journal-title":"J. Med Chem."},{"key":"10.1016\/j.critrevonc.2026.105205_bib116","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1158\/1078-0432.CCR-18-1959","article-title":"A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations","volume":"25","author":"Voss","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105205_bib117","first-page":"308","article-title":"Cancer treatment and survivorship statistics, 2025","volume":"75","author":"Wagle","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105205_bib118","doi-asserted-by":"crossref","first-page":"133","DOI":"10.18632\/oncotarget.28359","article-title":"Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability","volume":"14","author":"Wang","year":"2023","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105205_bib119","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1038\/s41388-018-0311-3","article-title":"FGFR1-ERK1\/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer","volume":"37","author":"Wang","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105205_bib120","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1158\/1078-0432.CCR-18-2779","article-title":"Adaptive Resistance to Dual BRAF\/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation","volume":"25","author":"Wang","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105205_bib121","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1158\/1535-7163.MCT-16-0261","article-title":"E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models","volume":"15","author":"Watanabe Miyano","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105205_bib122","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1158\/1535-7163.MCT-17-0174","article-title":"Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma","volume":"16","author":"Weeden","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105205_bib123","article-title":"Crystal Structure of the FGFR4\/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455","volume":"11","author":"Wu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2026.105205_bib124","doi-asserted-by":"crossref","first-page":"12089","DOI":"10.1039\/C8CC07546H","article-title":"LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance","volume":"54","author":"Wu","year":"2018","journal-title":"Chem. Commun. (Camb. )"},{"key":"10.1016\/j.critrevonc.2026.105205_bib125","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1981202","article-title":"Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer","volume":"13","author":"Xiang","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/j.critrevonc.2026.105205_bib126","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1055\/s-0044-1790230","article-title":"Expert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors","volume":"11","author":"Xu","year":"2024","journal-title":"Glob. Med Genet"},{"key":"10.1016\/j.critrevonc.2026.105205_bib127","doi-asserted-by":"crossref","DOI":"10.1080\/17458080.2024.2442305","article-title":"Computational revealing Infigratinib resistance to the FGFR2 N549H and N549K mutations","volume":"20","author":"Xu","year":"2025","journal-title":"J. Exp. Nanosci."},{"key":"10.1016\/j.critrevonc.2026.105205_bib128","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jtho.2023.12.023","article-title":"Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial","volume":"19","author":"Yang","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib129","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1158\/0008-5472.CAN-23-3195","article-title":"A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants","volume":"84","author":"Yang","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105205_bib130","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1242\/dmm.024760","article-title":"Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody","volume":"9","author":"Yin","year":"2016","journal-title":"Dis. Model Mech."},{"key":"10.1016\/j.critrevonc.2026.105205_bib131","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13046-017-0534-0","article-title":"FGF2\/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells","volume":"36","author":"Yuan","year":"2017","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105205_bib132","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-021-01040-2","article-title":"FGFR-TKI resistance in cancer: current status and perspectives","volume":"14","author":"Yue","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib133","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.3390\/cells10123363","article-title":"p38 Mediates Resistance to FGFR Inhibition in Non-Small Cell Lung Cancer","volume":"10","author":"Zarczynska","year":"2021","journal-title":"Cells Cells"},{"key":"10.1016\/j.critrevonc.2026.105205_bib134","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","article-title":"Targeting FGFR for cancer therapy","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib135","article-title":"FGF19 Is Coamplified With CCND1 to Promote Proliferation in Lung Squamous Cell Carcinoma and Their Combined Inhibition Shows Improved Efficacy","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib136","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/1535-7163.MCT-11-0306","article-title":"A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models","volume":"10","author":"Zhao","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105205_bib137","doi-asserted-by":"crossref","DOI":"10.1080\/17458080.2023.2264521","article-title":"Molecular docking and molecular dynamics simulations reveal the clinical resistance of the gatekeeper mutation V564F of FGFR2 against Infigratinib","volume":"18","author":"Zheng","year":"2023","journal-title":"J. Exp. Nanosci."},{"key":"10.1016\/j.critrevonc.2026.105205_bib138","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40164-024-00493-8","article-title":"Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice","volume":"13","author":"Zhou","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105205_bib139","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1039\/C9CC02052G","article-title":"Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4","volume":"55","author":"Zhou","year":"2019","journal-title":"Chem. Commun. (Camb. )"},{"key":"10.1016\/j.critrevonc.2026.105205_bib140","doi-asserted-by":"crossref","first-page":"490","DOI":"10.20892\/j.issn.2095-3941.2020.0120","article-title":"Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases","volume":"18","author":"Zhou","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.critrevonc.2026.105205_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102274","article-title":"45O First-in-human study of ABSK061: a selective fibroblast growth factor receptor (FGFR) 2\/3 inhibitor for treating patients with advanced solid tumors","volume":"9","author":"Zhu","year":"2024","journal-title":"ESMO Open"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:23:02Z","timestamp":1777605782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":141,"alternative-id":["S1040842826000922"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105205","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGFR-driven lung cancer: Dissecting resistance and exploring therapeutic avenues","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105205","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105205"}}